PURPOSE: This prospective, longitudinal study examined the effects of risk-adapted craniospinal irradiation (CSI) dose and the interactions of dose with age and time from diagnosis on intelligence quotient (IQ) and academic achievement (reading, spelling, and math) among patients treated for medulloblastoma (MB). PATIENTS AND METHODS: Patients received serial neurocognitive testing spanning from 0 to 6.03 years after diagnosis (median, 3.14 years). The multi-institutional study included 111 patients, who were 3 to 20 years of age at diagnosis (median age, 7.4 years), treated for MB with risk-adapted CSI followed by four cycles of high-dose chemotherapy (cyclophosphamide, cisplatin, and vincristine) with stem-cell support. High-risk patients (HR; n = 37) received CSI to 36 to 39.6 Gy and conformal boost treatment of the primary site to 55.8 to 59.4 Gy. Average-risk patients (AR; n = 74) received CSI to 23.4 Gy and conformal boost treatment of the posterior fossa to 36.0 Gy and primary site to 55.8 Gy. RESULTS: Multivariate modeling revealed statistically significant declines in mean IQ (-1.59 points/yr; P = .006), reading (-2.95 points/yr; P < .0001), spelling (-2.94 points/yr; P < .0001), and math (-1.87 points/yr; P = .003) scores for the entire group. The effects of risk-adapted radiation therapy on IQ, reading, and spelling were moderated by age, with the greatest rates of decline observed for the HR patients who were younger (< 7 years old) at diagnosis. CONCLUSION: Young age at diagnosis was the most prominent risk factor for neurocognitive deficits among survivors of MB despite reductions in CSI dosing and efforts to limit the boost volume. Younger patients exhibited substantial problems with the development of reading skills.
PURPOSE: This prospective, longitudinal study examined the effects of risk-adapted craniospinal irradiation (CSI) dose and the interactions of dose with age and time from diagnosis on intelligence quotient (IQ) and academic achievement (reading, spelling, and math) among patients treated for medulloblastoma (MB). PATIENTS AND METHODS: Patients received serial neurocognitive testing spanning from 0 to 6.03 years after diagnosis (median, 3.14 years). The multi-institutional study included 111 patients, who were 3 to 20 years of age at diagnosis (median age, 7.4 years), treated for MB with risk-adapted CSI followed by four cycles of high-dose chemotherapy (cyclophosphamide, cisplatin, and vincristine) with stem-cell support. High-risk patients (HR; n = 37) received CSI to 36 to 39.6 Gy and conformal boost treatment of the primary site to 55.8 to 59.4 Gy. Average-risk patients (AR; n = 74) received CSI to 23.4 Gy and conformal boost treatment of the posterior fossa to 36.0 Gy and primary site to 55.8 Gy. RESULTS: Multivariate modeling revealed statistically significant declines in mean IQ (-1.59 points/yr; P = .006), reading (-2.95 points/yr; P < .0001), spelling (-2.94 points/yr; P < .0001), and math (-1.87 points/yr; P = .003) scores for the entire group. The effects of risk-adapted radiation therapy on IQ, reading, and spelling were moderated by age, with the greatest rates of decline observed for the HR patients who were younger (< 7 years old) at diagnosis. CONCLUSION: Young age at diagnosis was the most prominent risk factor for neurocognitive deficits among survivors of MB despite reductions in CSI dosing and efforts to limit the boost volume. Younger patients exhibited substantial problems with the development of reading skills.
Authors: Shawna L Palmer; Wilburn E Reddick; John O Glass; Robert Ogg; Zoltan Patay; Dana Wallace; Amar Gajjar Journal: Brain Imaging Behav Date: 2010-06 Impact factor: 3.978
Authors: Irina Alimova; Sujatha Venkataraman; Peter Harris; Victor E Marquez; Paul A Northcott; Adrian Dubuc; Michael D Taylor; Nicholas K Foreman; Rajeev Vibhakar Journal: Int J Cancer Date: 2012-07-30 Impact factor: 7.396
Authors: Jasmine Lau; Christin Schmidt; Shirley L Markant; Michael D Taylor; Robert J Wechsler-Reya; William A Weiss Journal: Childs Nerv Syst Date: 2012-04 Impact factor: 1.475
Authors: Bree R Eaton; Saveli Goldberg; Nancy J Tarbell; Miranda P Lawell; Sara L Gallotto; Elizabeth A Weyman; Karen A Kuhlthau; David H Ebb; Shannon M MacDonald; Torunn I Yock Journal: Neuro Oncol Date: 2020-09-29 Impact factor: 12.300
Authors: Tara M Brinkman; Wilburn E Reddick; Joshua Luxton; John O Glass; Noah D Sabin; Deo Kumar Srivastava; Leslie L Robison; Melissa M Hudson; Kevin R Krull Journal: Neuro Oncol Date: 2012-09 Impact factor: 12.300
Authors: Stefan Rutkowski; Nicolas Ulrich Gerber; Katja von Hoff; Astrid Gnekow; Udo Bode; Norbert Graf; Frank Berthold; Günter Henze; Johannes E A Wolff; Monika Warmuth-Metz; Niels Soerensen; Angela Emser; Holger Ottensmeier; Frank Deinlein; Paul-Gerhardt Schlegel; Rolf-Dieter Kortmann; Torsten Pietsch; Joachim Kuehl Journal: Neuro Oncol Date: 2008-09-25 Impact factor: 12.300